EXACT Sciences Corporation (NASDAQ: EXAS) announced that a major gastroenterology journal has accepted for publication a multi-center, prospective study of EXACT’s Version 2 technology for early colorectal cancer detection using stool-based DNA testing. The study, conducted by Steven H. Itzkowitz, M.D, Professor of Medicine, Mount Sinai School of Medicine and his collaborators, was also recently presented in abstract form at Digestive Disease Week (DDW) in San Diego, California.

More: continued here

This entry was posted on Thursday, June 19th, 2008 at 7:06 am and is filed under GastroIntestinal / Gastroentorology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.